Lurbinectedin is a promising anticancer drug that has shown efficacy in various types of cancer. Recent studies suggest that it may also enhance the efficacy of immunotherapy. Immunotherapy is a type of cancer treatment that uses the body's immune system to fight cancer. Lurbinectedin may enhance immunotherapy efficacy by several mechanisms.

Firstly, Lurbinectedin has been shown to increase the expression of PD-L1, a protein that is often overexpressed in cancer cells and is a target for immunotherapy drugs such as checkpoint inhibitors. By increasing PD-L1 expression, Lurbinectedin may enhance the sensitivity of cancer cells to checkpoint inhibitors [1].

Secondly, Lurbinectedin has been shown to modulate the tumor microenvironment, making it more favorable for immune cells to infiltrate and attack cancer cells. Specifically, Lurbinectedin has been shown to decrease the number of immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells, while increasing the number of effector T cells and natural killer cells [2].

Finally, Lurbinectedin has been shown to induce immunogenic cell death, a type of cell death that triggers an immune response against cancer cells. Immunogenic cell death releases damage-associated molecular patterns (DAMPs) that activate immune cells and enhance their ability to recognize and attack cancer cells [3].

In conclusion, Lurbinectedin may enhance immunotherapy efficacy by increasing PD-L1 expression, modulating the tumor microenvironment, and inducing immunogenic cell death. Further studies are needed to fully understand the potential of Lurbinectedin as a combination therapy with immunotherapy.

Sources:
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165873/
[2] https://www.frontiersin.org/articles/10.3389/fonc.2023.1142081/full
[3] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN